Despite the increased interest in the role of NGAL in the early detection of renal damage after contrast exposure, few studies evaluated the additional benefit of a “point-of-care” assay to measure plasma levels of these biomarker, thus allowing a quick (about 20 minutes) evaluation of the patient’s risk of developing CI-AKI. Here, LCN2 is linked to acute kidney injury.